$SPRO News
Last published 1w ago
- 1w agoSPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today
- 1w agoSPROSpero Therapeutics to Present at Investor Conferences in NovemberGlobeNewswireCAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today
- 2w agoSPROSpero Therapeutics Strengthens Leadership Team to Advance Immunology PipelineGlobeNewswireAmy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapiesDae Gon Ha, Ph.D., appointed
- 3w agoSPROCHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - SPERO THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone, for today's our first session, we have Spiro Therapeutics. And on the stage with me is Esther Rajavili, the CEO of Spiro. Thanks for coming, Esther. Thank you for having us. Absolutely. We have ab
- 3w agoSPROCHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - SPERO THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone, for today's our first session, we have Spiro Therapeutics. And on the stage with me is Esther Rajavili, the CEO of Spiro. Thanks for coming, Esther. Thank you for having us. Absolutely. We have ab
- 3w agoSPROSpero Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
- 2mo agoSPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
- 2mo agoSPROSpero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
- 3mo agoSPROSpero Therapeutics Second Quarter 2026 Earnings Conference Call - SPERO THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Spiro Therapeutics Second Quarter 2026 Earnings Conference Call. Please be advised that this call is being recorded and a replay will be available. You can find the information on the r
- 3mo agoSPROSpero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business UpdateGlobeNewswireEntered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebipenem
- 3mo agoSPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
- 3mo agoSPROSpero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026GlobeNewswireCAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
- 3mo agoSPROSpero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical OfficerGlobeNewswireDr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseasesAppointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready
- 4mo agoSPROKKRSpero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & RoyaltiesGlobeNewswireFinancing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and
- 4mo agoSPROSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyGlobeNewswireUnder the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is
- 4mo agoSPROInnovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyPR NewswireInnovent Biologics, Inc. (01801.HK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced an exclusive license agreement for IBI355 (Spero R&D...
- 4mo agoACHFFSPROAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of DirectorsGlobeNewswireLONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated
- 4mo agoKLRACMPSSPROKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerGlobeNewswireWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen
- 4mo agoSPROANNUAL MEETING OF STOCKHOLDERS - SPERO THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to the 2026 Annual Meeting of Stockholders of Sparrow Therapeutics. It's 9 a.m. I'm Esther Rajavelu, the President, CEO, and CFO of the company, and I will be presiding at this meeting. Today's
- 4mo agoGSKSPROUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)Business WireFirst and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 More than 3 million cases of cUTIs are treated
- 4mo agoGSKSPROUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)GlobeNewswireFirst and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are treated annually in the
- 5mo agoCMPSSPROCompass Pathways Elects Kathleen Tregoning to Board of DirectorsBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of
- 6mo agoSPROSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateGlobeNewswireNew Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway guidance
- 6mo agoSPROSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026GlobeNewswireCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and
- 7mo agoSPROSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateGlobeNewswireSpero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's licensing partner,
- 10mo agoSPROSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisGlobeNewswireCAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and
- 11mo agoSPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and
- 12mo agoSPROSpero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business UpdateGlobeNewswireResults from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025Spero's development partner, GSK, plans to submit data from the
- 1y agoSPROSpero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025GlobeNewswireCAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and
- 1y agoGSKSPROPIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)GlobeNewswireData presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with regulatory
- 1y agoSPROSpero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeekGlobeNewswireCAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and
- 1y agoSPROSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSPROSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateGlobeNewswirePIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its
- 1y agoSPROSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025GlobeNewswireCAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and
- 1y agoSPROSpero, Yechezkal et al. vs Porsche Cars of North America - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoSPROSpero, Yechezkal et al. vs Volkswagen Group of America, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoGSKSPROSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeGlobeNewswireIf approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many
- 1y agoSPROSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateGlobeNewswirePre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2
- 1y agoSPROSpero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025GlobeNewswireCAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and
- 1y agoSPROSpero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerGlobeNewswireCAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and
- 1y agoSPROSpero, Yechezkal et al. vs Volkswagen Group of America, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoSPROSpero, Yechezkal et al. vs Porsche Cars of North America - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoSPROSpero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateGlobeNewswirePre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set
- 1y agoSPROSpero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025GlobeNewswireCAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
- 1y agoSPROUPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for
- 1y agoSPROSpero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for
- 1y agoSPROSpero, Yechezkal et al. vs Mercedes-Benz USA, LLC et al. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 1y agoSPROSpero, Yechezkal et al. vs Mercedes-Benz USA, LLC et al. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 1y agoSPROSpero, Yechezkal et al. vs Mercedes-Benz USA, LLC et al. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 1y agoSPROSpero Therapeutics Provides Business Update and Announces Interim Leadership ChangesGlobeNewswireEsther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from the SEC Relating